Loading company…
M.A. Med Alliance develops interventional cardiovascular devices, including drug-eluting balloons.
Founded in 2008 and based in Nyon, Switzerland, M.A. Med Alliance develops and manufactures interventional cardiovascular products, including the SELUTION SLR™ Drug-Eluting Balloon. Cordis Corporation acquired the company in October 2022 in a deal valued at up to USD 1.135 billion, including an upfront payment of USD 235 mn and additional milestones through 2029.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in